Cortical inhibitory neurons that express vasoactive intestinal peptide (VIP) became markedly underactive in the motor cortex of Huntington's disease model mice, and reactivating them with light restored more normal network activity and improved a learned motor task, according to a study published in Nature on 1 July 2026 by Sonja Blumenstock, Irina Dudanova, Takaki Komiyama and colleagues at the University of California San Diego and in Germany. Using longitudinal in vivo two-photon calcium imaging, the team followed three inhibitory neuron subtypes (VIP, somatostatin and parvalbumin) alongside excitatory corticostriatal projection neurons in R6/2 mice as the disease progressed, while the animals performed a head-fixed motorized ladder task. The imaging in the earlier preprint version of the work ran across roughly four to five weeks, spanning early, middle and late stages in this fast-progressing model.

The pattern was subtype specific rather than general. VIP interneurons showed almost no movement-related activity in R6/2 mice, somatostatin interneurons were instead hyperactive during movement, and corticostriatal projection neurons were hypoactive. The authors report that VIP interneuron, somatostatin interneuron and corticostriatal changes were also seen in zQ175DN knock-in mice, a slower model closer to the genetics of adult-onset disease. "Cortical inhibitory cells have received little attention in Huntington's disease," Dudanova said in the university's announcement, noting that some cell types were overactive and some nearly silent.

When the researchers used optogenetics, a technique that makes selected neurons respond to light after they have been genetically modified, selective activation of VIP interneurons in R6/2 mice acutely raised corticostriatal neuron activity. With repeated stimulation, the paper reports a sustained improvement in corticostriatal activity levels, restoration of healthier activity in the VIP cells themselves, and easing of motor deficits, with behavioural improvement persisting for days after the light was switched off. That persistence is the part the authors treat as most consequential, because it suggests the circuits changed rather than simply responding while stimulated.

The counterpoint is scale and species. R6/2 is a rapid, early-onset transgenic model, and the authors state in the paper that it does not capture all features of adult-onset Huntington's disease in people, which is why the zQ175DN comparison was added. Optogenetics as used here requires viral delivery of light-sensitive proteins and an implanted light source in the mouse skull, and is not a treatment available to people; the investigators point instead to non-invasive stimulation methods as a direction for future work. Nothing in the study alters the underlying CAG repeat expansion in the huntingtin gene, and no human data are reported.